secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001297184-22-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q4 revenue $120.9M, GAAP EPS $0.39; full-year net income $62.1M
-------------------------------------------------------------------------

- Q4 net revenues $120.9M vs $95.9M in Q4 2020, up 26%; GAAP net income $19.8M vs loss of $6.3M.
- Full-year net revenues $437.8M vs $349.8M in 2020; GAAP net income $62.1M vs $1.4M.
- Adjusted non-GAAP diluted EPS $0.42 for Q4 and $1.37 for full year.
- CEO cites continued growth of higher-margin products and expects pipeline milestones in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000003/0001297184-22-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000003/amph-20220310x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-22-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer